Fact based stock research
Mochida Pharmaceutical (TSE:4534)
JP3922800002
Mochida Pharmaceutical stock research in summary
Mochida Pharmaceutical shares have a market-typical stock price level. They are safely financed and are good value, but show below average growth. We recommend evaluating whether the future of the company Mochida Pharmaceutical is typical for this industry which the market average price level of the shares suggests. If you believe that the future of the company is above average, that could be an argument for buying the shares and vice versa.
Latest Obermatt Ranks
Value Rank | 61 | ![]() |
Growth Rank | 36 | ![]() |
Safety Rank | 100 | ![]() |
Combined Rank | 77 | ![]() |
Country | Japan |
Industry | Pharmaceuticals |
Index | |
Size class | Large |
March 26, 2021. Stock data may be delayed. Login to get the most recent research.
Google: Mochida Pharmaceutical
Research History: Mochida Pharmaceutical
RESEARCH HISTORY | 2018 | 2019 | 2020 | 2021 | ||||
---|---|---|---|---|---|---|---|---|
VALUE | ||||||||
VALUE | n/a |
![]() |
n/a |
![]() |
80 |
![]() |
61 |
![]() |
GROWTH | ||||||||
GROWTH | n/a |
![]() |
n/a |
![]() |
31 |
![]() |
36 |
![]() |
SAFETY | ||||||||
SAFETY | n/a |
![]() |
n/a |
![]() |
100 |
![]() |
100 |
![]() |
COMBINED | ||||||||
COMBINED | n/a |
![]() |
n/a |
![]() |
84 |
![]() |
77 |
![]() |
Value Metrics in Detail
VALUE METRICS | 2018 | 2019 | 2020 | 2021 | ||||
---|---|---|---|---|---|---|---|---|
PRICE VS. REVENUES (P/S) | ||||||||
PRICE VS. REVENUES (P/S) | n/a |
![]() |
n/a |
![]() |
66 |
![]() |
50 |
![]() |
PRICE VS. PROFITS (P/E) | ||||||||
PRICE VS. PROFITS (P/E) | n/a |
![]() |
n/a |
![]() |
51 |
![]() |
41 |
![]() |
PRICE VS. CAPITAL (Market-to-Book) | ||||||||
PRICE VS. CAPITAL (Market-to-Book) | n/a |
![]() |
n/a |
![]() |
80 |
![]() |
72 |
![]() |
DIVIDEND YIELD | ||||||||
DIVIDEND YIELD | n/a |
![]() |
n/a |
![]() |
74 |
![]() |
72 |
![]() |
CONSOLIDATED RANK: VALUE | ||||||||
CONSOLIDATED RANK: VALUE | n/a |
![]() |
n/a |
![]() |
80 |
![]() |
61 |
![]() |
Growth Metrics in Detail
GROWTH METRICS | 2018 | 2019 | 2020 | 2021 | ||||
---|---|---|---|---|---|---|---|---|
REVENUE GROWTH | ||||||||
REVENUE GROWTH | n/a |
![]() |
n/a |
![]() |
30 |
![]() |
34 |
![]() |
PROFIT GROWTH | ||||||||
PROFIT GROWTH | n/a |
![]() |
n/a |
![]() |
69 |
![]() |
58 |
![]() |
STOCK RETURNS | ||||||||
STOCK RETURNS | n/a |
![]() |
n/a |
![]() |
30 |
![]() |
34 |
![]() |
CONSOLIDATED RANK: GROWTH | ||||||||
CONSOLIDATED RANK: GROWTH | n/a |
![]() |
n/a |
![]() |
31 |
![]() |
36 |
![]() |
Safety Metrics in Detail
SAFETY METRICS | 2018 | 2019 | 2020 | 2021 | ||||
---|---|---|---|---|---|---|---|---|
LEVERAGE | ||||||||
LEVERAGE | n/a |
![]() |
n/a |
![]() |
96 |
![]() |
92 |
![]() |
REFINANCING | ||||||||
REFINANCING | n/a |
![]() |
n/a |
![]() |
71 |
![]() |
64 |
![]() |
LIQUIDITY | ||||||||
LIQUIDITY | n/a |
![]() |
n/a |
![]() |
97 |
![]() |
98 |
![]() |
CONSOLIDATED RANK: SAFETY | ||||||||
CONSOLIDATED RANK: SAFETY | n/a |
![]() |
n/a |
![]() |
100 |
![]() |
100 |
![]() |
Stock analysis by the purely financial fact-based Obermatt Method for the investment strategies Value, Growth and Safety for Mochida Pharmaceutical from March 26, 2021.
We invest in our stock tips ourselves and openly publish the returns of our portfolio. That's how much we believe in our stock research. Subscribe to the top 10 stocks for 100 markets conveniently by e-mail.